BAY 60-4552
BAY 60-4552
BAY 60-4552 is a chemical compound that has been studied for its potential therapeutic effects, particularly in the context of cardiovascular diseases. It is known to act as a selective inhibitor of the enzyme soluble guanylate cyclase (sGC), which plays a crucial role in the nitric oxide (NO) signaling pathway.
Mechanism of Action[edit | edit source]
BAY 60-4552 functions by modulating the activity of soluble guanylate cyclase, an enzyme that catalyzes the conversion of GTP to cyclic GMP (cGMP). This process is a key component of the NO signaling pathway, which is involved in vasodilation and the regulation of blood pressure. By inhibiting sGC, BAY 60-4552 can influence the levels of cGMP, thereby affecting vascular tone and potentially offering therapeutic benefits in conditions characterized by impaired NO signaling.
Pharmacological Effects[edit | edit source]
The pharmacological effects of BAY 60-4552 have been explored in various preclinical studies. It has been shown to:
- Enhance vasodilation by increasing cGMP levels in vascular smooth muscle cells.
- Potentially improve endothelial function in conditions where NO production is compromised.
- Exhibit protective effects in models of cardiovascular disease, such as hypertension and heart failure.
Clinical Research[edit | edit source]
As of the latest updates, BAY 60-4552 is primarily in the research phase, with studies focusing on its efficacy and safety profile. Clinical trials are necessary to determine its potential as a therapeutic agent in humans.
Potential Applications[edit | edit source]
BAY 60-4552 may have applications in the treatment of:
- Hypertension
- Heart failure
- Pulmonary arterial hypertension
- Other cardiovascular disorders where NO signaling is disrupted
Safety and Side Effects[edit | edit source]
The safety profile of BAY 60-4552 is still under investigation. Preclinical studies suggest that it is generally well-tolerated, but further research is needed to fully understand its side effects and potential interactions with other medications.
Also see[edit | edit source]
- Soluble guanylate cyclase
- Nitric oxide signaling
- Cyclic GMP
- Vasodilation
- Cardiovascular pharmacology
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
